SCHEMBL2643735

SCHEMBL2643735

CCOC(=O)C(=NOC1CCCC1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.43
TAS1R3 Q7RTX0 2/20 0.40
ATM Q13315 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLC6A3 Q01959 3/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
KDM2B Q8NHM5 1/20 0.38
HCRTR1 O43613 1/20 0.38
HPGD P15428 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRK1 P41145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643733 1.00 TSHR (0.49) TSHRKMT2ATAS1R3ATMTAS1R2
SCHEMBL2644757 0.82 TSHR (0.44) TSHRKMT2ATAS1R3ATMTAS1R2
SCHEMBL2644756 0.82 TSHR (0.44) TSHRKMT2ATAS1R3ATMTAS1R2
SCHEMBL2666834 0.80 ALDH1A1 (0.40) TSHRKMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL2643957 0.79 KMT2A (0.42) KMT2AALDH1A1SMN1; SMN2HTTLMNA
SCHEMBL2643960 0.79 KMT2A (0.42) KMT2AALDH1A1SMN1; SMN2HTTLMNA
SCHEMBL2644493 0.74 GCK (0.40) TAS1R3TAS1R2TAS1R1ALDH1A1
SCHEMBL2644496 0.74 GCK (0.40) TAS1R3TAS1R2TAS1R1ALDH1A1
SCHEMBL2644451 0.73 GCK (0.40) KMT2ATAS1R3TAS1R1ALDH1A1SMN1; SMN2
SCHEMBL2644455 0.73 GCK (0.40) KMT2ATAS1R3TAS1R1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902248-B2 C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus HOFFMANN-LA ROCHE INC. (US) 2011-03-08 US disclosed
US-20080146625-A1 C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus BERTHEL STEVEN JOSEPH 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146625-A1 C-(Heteroarylaminocarbonyl)-3-phenyl-oxime, e.g., N-Benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-isopropoxyiminoacetamide and 2-(3-Chloro-4-methanesulfonyl-phenyl)-2-cyclopentyloxyimino-N-(5-methyl-thiazol-2-yl)acetamide; treating metabolic diseases, especially type II diabetes mellitus GCK, PC, PCK2 TSHR 2310/4885KMT2A 967/4885TAS1R3 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.